Kyowa Kirin, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1949-01-01

Employees: 7.1K

Market Cap: $12B

Website: http://www.kyowa-kirin.co.jp/

Clinical Trials

KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

Phase 1

Terminated

Conditions: Urothelial Carcinoma

Interventions: Drug: KHK2455
Drug: Avelumab

First Posted Date: 2019-04-16

Last Posted Date: 2024-04-25

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 16

Registration Number: NCT03915405

Locations: 🇺🇸
Kyowa Research Site USA005, Iowa City, Iowa, United States
🇺🇸
Kyowa Research Site USA 009, Houston, Texas, United States
🇪🇸
Kyowa Research Site ESP003, Barcelona, Spain

and more 6 locations

Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: KHK4083
Drug: Placebo

First Posted Date: 2018-10-11

Last Posted Date: 2024-04-26

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 274

Registration Number: NCT03703102

Locations: 🇯🇵
Kyowa Investigational Site JP-25, Shimane, Japan
🇺🇸
Kyowa Investigational Site US-02, Dallas, Texas, United States
🇩🇪
Kyowa Investigational Site GE-14, Berlin, Germany

and more 55 locations

Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH

Phase 3

Completed

Conditions: X-Linked Hypophosphatemia

Interventions: Biological: burosumab
Drug: Oral Phosphate Supplement
Drug: active vitamin D

First Posted Date: 2016-09-27

Last Posted Date: 2024-08-29

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 61

Registration Number: NCT02915705

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States

and more 13 locations

KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor
Cancer
Carcinoma

Interventions: Drug: KHK2455
Drug: Mogamulizumab

First Posted Date: 2016-08-15

Last Posted Date: 2024-04-25

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 36

Registration Number: NCT02867007

Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)

Phase 2

Completed

Conditions: X-Linked Hypophosphatemia

Interventions: Biological: Burosumab

First Posted Date: 2016-04-25

Last Posted Date: 2024-05-06

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 13

Registration Number: NCT02750618

Locations: 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
Shriners Hospital for Children, Saint Louis, Missouri, United States

Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Hepatocellular Carcinoma
HCC
Solid Tumor
Cancer
Carcinoma

Interventions: Biological: Mogamulizumab + Nivolumab

First Posted Date: 2016-03-10

Last Posted Date: 2024-04-25

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 114

Registration Number: NCT02705105

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis
Digestive System Diseases
Colitis, Ulcerative
Colitis
Gastrointestinal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases
Colonic Diseases
Autoimmune Disease
Abdominal Pain

Interventions: Drug: KHK4083
Drug: Placebo

First Posted Date: 2016-01-06

Last Posted Date: 2024-04-26

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 66

Registration Number: NCT02647866

Locations: 🇷🇸
Bežanija Kosa, Belgrade, Serbia

Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)

Phase 3

Completed

Conditions: X-linked Hypophosphatemia

Interventions: Biological: burosumab

First Posted Date: 2015-09-01

Last Posted Date: 2024-06-18

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 14

Registration Number: NCT02537431

Locations: 🇺🇸
Yale University School of Medicine - Yale New-Haven Hospital/Yale Center for Clinical Investigation, New Haven, Connecticut, United States
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇺🇸
Indiana University Department of Medicine University Hospital, Indianapolis, Indiana, United States

and more 11 locations

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

Phase 3

Completed

Conditions: X-linked Hypophosphatemia

Interventions: Biological: burosumab
Other: Placebo

First Posted Date: 2015-08-18

Last Posted Date: 2024-06-18

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 134

Registration Number: NCT02526160

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

and more 22 locations

Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: mogamulizumab
Drug: Docetaxel

First Posted Date: 2015-02-09

Last Posted Date: 2018-11-30

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 13

Registration Number: NCT02358473

Locations: 🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸
John Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸
Horizon Oncology, Lafayette, Indiana, United States

and more 2 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy